Serelaxin Rejection Shows “Breakthrough” Status Doesn’t De-Risk Programs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA “complete response” appears to be the first for a product under the expedited pathway. But Novartis has a second trial that could support resubmission in 2016, and two other late-stage heart failure drugs in the pipeline.